Moderna (MRNA)
(Delayed Data from NSDQ)
$125.14 USD
+3.66 (3.01%)
Updated Jul 16, 2024 04:00 PM ET
Pre-Market: $124.75 -0.39 (-0.31%) 8:54 AM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$125.14 USD
+3.66 (3.01%)
Updated Jul 16, 2024 04:00 PM ET
Pre-Market: $124.75 -0.39 (-0.31%) 8:54 AM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Moderna (MRNA) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $172.26 in the latest trading session, marking a -1.52% move from the prior day.
Moderna ETFs Rallying on COVID-19 Vaccine Booster Shot Update
by Sweta Jaiswal, FRM
Moderna has been rallying on the latest positive booster shot-related update.
Company News for Mar 30, 2022
by Zacks Equity Research
Companies In The News Are: FDX, UNH, LHCG, MRNA, ESLT.
FDA Authorizes Pfizer, Moderna's Second COVID Booster Dose
by Kinjel Shah
The FDA authorized a second booster dose of COVID-19 vaccines made by Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for older adults and some immunocompromised individuals.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $179.68, moving +0.53% from the previous trading session.
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Biotech Stock Roundup: BMY's Drug Approval, MRNA's Vaccine Update & More
by Zacks Equity Research
Pipeline and regulatory updates from Bristol Myers (BMY) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
by Zacks Equity Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
FDA Panel to Discuss Fourth Booster Dose in April Meeting
by Kinjel Shah
The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.
The Zacks Analyst Blog Highlights Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu
by Zacks Equity Research
Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu have been highlighted in this Analyst Blog.
Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab
by Zacks Equity Research
Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.
5 Stocks in Nasdaq ETF That Gained Most Last Week
by Sweta Killa
The Nasdaq Index logged in the best weekly gain since November 2020 fueled by the Fed¿¿¿s decision to raise interest rates for the first time since 2018 and progress in the Russia-Ukraine peace talks
The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna
by Zacks Equity Research
J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.
What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $168.26 in the latest trading session, marking a -0.65% move from the prior day.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
by Zacks Equity Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.
China's COVID-19 Lockdown Brings Back Focus on Healthcare ETFs
by Sweta Jaiswal, FRM
Let's take a look at some healthcare ETFs that are regaining popularity among investors as COVID-19 cases rise in China.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up
by Zacks Equity Research
Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.
Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Moderna (MRNA) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $138.20, marking a -0.95% move from the previous day.